Depression and the gut-brain axis: what the microbiome has to do with it
Gut and head talk to each other, in both directions. That is well established. But the road from gut to head runs differently than almost everywhere online suggests.
If you are in a very bad place right now
This article is a guide. It is not help in an acute crisis. If you are thinking about suicide, want to hurt yourself, or feel that you cannot bear it any longer, please get help immediately. Immediately means now and not after reading.
- Telefonseelsorge (German crisis line): 0800 111 0 111 and 0800 111 0 222, around the clock, free of charge and anonymous.
- In acute danger: 112, the German emergency number.
- Nearest psychiatric hospital or emergency department: someone can open the door for you there at any hour of the day or night, without an appointment and without a referral.
The numbers listed here are German numbers. If you are reading this from another country, please use the crisis line and the emergency number of the country you are in.
This applies even when you do not believe yourself right now that it is bad enough. These numbers are made for exactly this moment.
All articles from the gut cluster
Real lines run between gut and head, and that is well established. Depression is still not a bowel disease. The gut-brain axis is an additional perspective, not a replacement explanation, and it replaces neither psychotherapy nor psychiatric treatment.
You are sitting on the edge of the bed and the day lies ahead of you like a mountain. Not sad in the sense of crying. More like switched off. And your gut is not playing along either, and has not been for weeks.
At some point you type three words into your phone at night. Gut, serotonin, depression. And the first page tells you that 95 percent of your happiness hormone sits in your gut.
Many people know this pattern. The sentence sounds like an explanation. It sounds like a door nobody had opened before. And it is even half right.
It just does not hold. The serotonin from your gut never arrives in your head. There is a connection between gut and mood, quite an elegant one in fact, but it runs differently. And that matters, because a great deal of product advertising has been built on that one wrong shortcut.
I am writing this article as a physician who takes both seriously: psychiatry with its restraint and microbiome research with its curiosity. Both have good reasons. What I give you here are the numbers, where the numbers come from, and the points at which they stop holding.
What you will find in this article
- The four lines between gut and brain, in both directions
- Why the serotonin argument does not hold in this form
- Tryptophan and kynurenine: the route that is plausible
- Which famous findings come from mice
- Bravo 2011 and the severed vagus nerve
- What large human cohorts have found
- Probiotics: effect sizes without the marketing
- The nutrition trail with SMILES and Firth
- Inflammation, CRP and the subgroup idea
- Depression in irritable bowel syndrome and in inflammatory bowel disease
- Why no stool test can detect a depression
- Red flags where things should not wait
Four lines between gut and head
Do you know the feeling that your gut already knows before your head has put it into words? Before an exam, before a difficult conversation, before a message you do not want to open.
That is neither imagination nor metaphor. Between gut and brain there are four established communication routes, and they all work in both directions.
The four routes along which gut and brain stay in contact
1. The vagus nerve
The direct data line. By far the largest share of its fibres reports upwards rather than downwards. The gut therefore sends considerably more than it receives.
gut to head and back2. The immune system
The gut lining is one of the largest contact surfaces between your body and the outside world, and correspondingly much immune tissue sits there. What these cells release in messengers, interleukin 6 for example, can arrive in the brain and alter signalling pathways there.
chemical radio3. Microbial metabolites
When bacteria ferment fibre, short-chain fatty acids such as butyrate arise. They supply the gut lining and interfere with immune and nerve signals.
by-products with side effects4. The stress axis
Hypothalamus, pituitary and adrenal gland, HPA axis for short. It governs cortisol. Its sensitivity is shaped early in life, and gut bacteria have a share in that.
hormonal lineSource for this outline: the large review by the group around Cryan in Cork [Mechanism Review], supplemented by the Leuven review on short-chain fatty acids and the review by the group around Mayer on the blood-brain barrier.
Who did it. A group around Cryan in Cork assembled the most comprehensive overview of the microbiota-gut-brain axis to date in Physiological Reviews in 2019.
What they observed. As communication routes they name the immune system, tryptophan metabolism, the vagus nerve together with the enteric nervous system, and microbial metabolites such as short-chain fatty acids, branched-chain amino acids and peptidoglycans. Infection, mode of birth, antibiotics, diet, environmental stress and the host's genes count as shaping factors. The authors state explicitly that the mechanistic evidence comes predominantly from animal models.
What that means for you. The connection itself is not a fringe opinion. It stands in one of the most respected physiological review journals. What follows from it for an individual person is explicitly not stated there.
Cryan JF et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877-2013. DOI: 10.1152/physrev.00018.2018 [Mechanism Review]Bidirectional is the decisive word here. Stress changes the composition of your gut flora. And the composition of your gut flora changes how your stress axis answers.
That is uncomfortable, because it destroys the simple narrative. There is no clean cause and no clean consequence. There is a circle, and you can enter it at several points.
How the axis works in detail and how the vagus nerve can be addressed deliberately, I have written up separately. You will find the mechanism together with breathing, cold and transcutaneous stimulation in Gut-brain axis and vagus stimulation.
Most texts ask: does depression come from the gut? That question is put wrongly, because it presumes a one-way street.
The usable question runs: is there a point in this circuit where something could be moved without leaving everything else out? That is a more modest question. It has the advantage of being answerable.
And now you know why the topic of gut and mood so rarely turns on a single cause. It turns on four lines that are all on the phone at once.
The correction: serotonin from the gut does not reach the brain
Now to the sentence that probably brought you here. It runs roughly like this: 95 percent of serotonin is made in the gut, so mood sits in the belly.
The first part is right. The second part does not follow from it.
Who did it. A group around Yano investigated in Cell in 2015, in mice and in cell cultures, how gut bacteria influence serotonin production.
What they observed. Spore-forming bacteria from mouse and from human flora promoted serotonin production in the enterochromaffin cells of the colon. These cells supply the mucosa, the gut lumen and the circulating platelets. Certain microbial metabolites raised serotonin levels in chromaffin cell cultures and in germ-free mice. What changed as a result were gut motility and platelet function.
What that means for you. Yes, bacteria have an influence on serotonin. What was measured were consequences for digestion and blood clotting, not for mood. And it was measured in mice and cells [In vivo, mouse] [In vitro].
Yano JM et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-76. DOI: 10.1016/j.cell.2015.02.047 [In vivo, mouse] [In vitro]And here comes the point that is missing from almost every popular account. For serotonin from enterochromaffin cells there is to this day no evidence that it crosses the blood-brain barrier. That is basic physiology, and the review by the group around Mayer in Los Angeles describes the blood-brain barrier as exactly the place that regulates how much information from the gut arrives upstairs at all.
Picture the blood-brain barrier as the bouncer at a club. Serotonin is on no guest list. It does not get in, no matter how much of it waits outside.
The serotonin in your brain is therefore made in the brain itself. The raw material for it is tryptophan, an amino acid from food. And tryptophan does come through the door.
The route that is plausible: tryptophan and kynurenine
- Tryptophan reaches the blood from food. It is the building block from which serotonin arises in the brain.
- In the gut lining sits an enzyme called indoleamine 2,3-dioxygenase. It diverts tryptophan onto a different route, the kynurenine pathway. Inflammatory signals crank this enzyme up.
- Kynurenine can cross the blood-brain barrier. It uses the same transporter as tryptophan for this, LAT1. So both compete for the same door.
- The more tryptophan is diverted towards kynurenine, the less is available upstairs for serotonin production. In addition, kynurenine derivatives arise that act at glutamate receptors.
- Bacteria join in at several points: through inflammatory signals, through their own tryptophan pathways and through how permeable the lining happens to be.
Where this sits: mechanistically plausible and visible in human blood values. That a treatment could be derived from it is not thereby said.
Who did it. A group around Marx pooled 101 studies with a combined 10,912 participants on kynurenine metabolism in depression, bipolar disorder and schizophrenia in Molecular Psychiatry in 2021.
What they observed. Tryptophan and kynurenine were reduced across all three diagnoses. Kynurenic acid and the ratio of kynurenic acid to quinolinic acid were reduced in affective disorders. The ratio of kynurenine to tryptophan was raised in depression and schizophrenia. The authors read this as a shift away from the serotonin route and towards the kynurenine route.
What that means for you. This shift is measurable in humans. It is neither a test nor diagnosis-specific, though, because it shows up in three very different illnesses.
Marx W et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021;26(8):4158-4178. DOI: 10.1038/s41380-020-00951-9 [Meta-analysis, k=101, n=10,912]The same applies to a second candidate. Bacteria in the gut make GABA, the most important damping messenger of the brain. By current understanding, this GABA does not reach the brain directly either. It might take influence through the enteric nervous system and possibly through the vagus, but not as a messenger that travels upstairs itself.
The serotonin narrative is not annoying because it would be false. It is annoying because it is too small.
The connection that actually shows up in numbers in humans is the one running through tryptophan, inflammation and kynurenine. That one is more complicated, less suited to advertising and considerably more interesting.
And now you know why a product advertising the happiness hormone from the gut does you no harm, but also does not explain what it claims to explain.
What mouse experiments show, and what they do not
When you read a dramatic sentence about gut and mind online, it very probably comes from an animal experiment. That is not an accusation. The strongest causal evidence in this whole field of research comes from the lab, and it really is impressive.
It just happens to be from the lab. That is why I mark every single one of these papers here as what it is.
Who did it. A Japanese group around Sudo compared germ-free mice with normally colonised animals in the Journal of Physiology in 2004 [In vivo, mouse].
What they observed. After immobilisation stress, ACTH and corticosterone rose considerably more in germ-free animals than in those raised pathogen-free. The germ-free animals also had less BDNF in cortex and hippocampus. The overshooting stress response could be dampened by Bifidobacterium infantis and partly balanced out by colonisation with normal stool, though only within an early window of development.
What that means for you. Bacteria help shape the stress axis, and there is a window for it. About an adult human being in the year 2026, this finding says nothing yet.
Sudo N et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263-75. DOI: 10.1113/jphysiol.2004.063388 [In vivo, mouse]And then comes the paper everything revolves around. It is from 2011, it stands in the Proceedings of the National Academy of Sciences, and it is the most elegant piece of evidence in this literature.
Who did it. A group around Bravo, with Cryan and Bienenstock on the author team, fed BALB/c mice Lactobacillus rhamnosus JB-1 continuously [In vivo, mouse].
What they observed. The animals showed less stress-induced corticosterone as well as less anxiety-like and depression-like behaviour. In various brain regions the amount of GABA receptor blueprints changed, with increases in the cingulate and prelimbic cortex and simultaneous decreases in hippocampus, amygdala and locus coeruleus. The decisive part came at the end: in mice whose vagus nerve had been severed, neither the neurochemical nor the behavioural change was found. Nothing of it was left.
What that means for you. No line, no signal. The vagus is not a side route but, in this model, the route. That is a clean piece of mechanistic evidence and still a mouse experiment with a single bacterial strain.
Bravo JA et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050-5. DOI: 10.1073/pnas.1102999108 [In vivo, mouse]The third building block are the transfer experiments. They sound like science fiction and are nonetheless cleanly done.
Who did it. A group around Zheng transferred stool from people with major depression and from healthy controls into germ-free mice in Molecular Psychiatry in 2016 [In vivo, mouse]. Almost at the same time, a group around Kelly transferred stool from 34 depressed people and 33 matched controls into rats whose own flora had previously been strongly depleted, in the Journal of Psychiatric Research [In vivo, rat].
What they observed. The recipient animals with the so-called depression microbiota showed depression-like behaviour and shifts in carbohydrate and amino acid metabolism. In the Kelly work, anhedonia and anxiety-like behaviour came on top, as well as changes in tryptophan metabolism. In the human donors themselves, richness and diversity of the gut flora were reduced.
What that means for you. Something transferable appears to sit in the stool. Two independent groups have shown that. Both showed it in rodents, and the number of humans involved was small.
Zheng P et al. Mol Psychiatry. 2016;21(6):786-96. DOI: 10.1038/mp.2016.44 · Kelly JR et al. J Psychiatr Res. 2016;82:109-18. DOI: 10.1016/j.jpsychires.2016.07.019 [In vivo, mouse] [In vivo, rat]Why a mouse does not have depression
Here comes the paragraph almost nobody writes. A mouse cannot be depressed. It can behave as though it were.
The best known test is called the forced swimming test. A mouse is placed in a water container it cannot get out of, and the time it spends no longer moving is measured. Less movement counts as depression-like.
That measures behaviour. It does not measure experience. No animal model captures hopelessness, guilt, the loss of meaning, or the thought that things would be better without oneself. Yet precisely these things make up the illness this article is about.
When somewhere it says a bacterium improved depression, three questions are worth asking. First: human or animal? Second: which endpoint was measured, a questionnaire or a behaviour in a water tank? Third: was it tested in addition to ongoing treatment or instead of it?
The third question decides the most in practice. In almost every study that found something, the measure came in addition.
Animal data are not worthless because they are animal data. They answer a different question from the one you have.
They answer: is a mechanism possible at all? Answer: yes, impressively so. They do not answer: does this happen in me too? That second question needs humans, and plenty of them.
And now you know why I change the tone in the next section. In humans it gets quieter.
What studies in humans have found, and where they contradict each other
In humans you cannot take bacteria away and then look at what happens. You can count, compare and search for connections. That is weaker, but it is what we have.
Who did it. A Belgian group around Valles-Colomer examined the gut flora of 1054 people from the Flemish Gut Flora Project in Nature Microbiology in 2019 and checked the findings in a further 1070 people.
What they observed. Butyrate-producing Faecalibacterium and Coprococcus were consistently associated with higher quality of life. Coprococcus and Dialister were reduced in depression, and remained so even after correcting for antidepressant intake. The bacterial production potential for a dopamine derivative was positively related to mental quality of life.
What that means for you. These are associations and not causes. The correction for antidepressants is nonetheless notable, because it takes out one of the strongest confounders.
Valles-Colomer M et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-632. DOI: 10.1038/s41564-018-0337-x [Cohort, n=1054 plus 1070]Who did it. A group around Radjabzadeh analysed 1054 participants of the Rotterdam Study in Nature Communications in 2022 and checked the results in the Amsterdam HELIUS cohort with 1539 people.
What they observed. 13 taxa were related to depressive symptoms, among them Eggerthella, Subdoligranulum, Coprococcus, Sellimonas, Lachnoclostridium, Hungatella, several Ruminococcaceae groups and Eubacterium ventriosum. These bacteria are involved in the production of glutamate, butyrate, serotonin and GABA.
What that means for you. Coprococcus thereby turns up in two independent European cohorts. That is the most robust replication currently available.
Radjabzadeh D et al. Gut microbiome-wide association study of depressive symptoms. Nat Commun. 2022;13(1):7128. DOI: 10.1038/s41467-022-34502-3 [Cohort, n=1054 plus 1539]And now the brake block
At this point you could write an enthusiastic article. Two large cohorts, a replicated finding, a plausible mechanism. There is only one paper that gets in the way, and it is the largest of them all.
The same pattern in four different diagnoses
A group around Nikolova summarised 59 case-control studies on depression, bipolar disorder, psychosis, schizophrenia, anorexia, anxiety, obsessive-compulsive disorder, PTSD and ADHD in JAMA Psychiatry in 2021. The analysis of alpha diversity rested on 34 studies with 1519 patients against 1429 controls.
Microbial richness was reduced, with standardised mean differences of minus 0.26 for observed species and minus 0.5 for the Chao1 index. This finding was consistent only in bipolar disorder, though. For Shannon and Simpson there was no difference at all.
The decisive sentence concerns the individual bacteria. For relative abundance there was little indication of diagnosis specificity. Instead a transdiagnostic pattern showed up: less Faecalibacterium and Coprococcus, more Eggerthella, and that equally in depression, bipolar disorder, psychosis and anxiety.
That answers one core question of this article. A finding that looks the same across four different illnesses cannot indicate any single one of them.
Source: Nikolova VL et al. Perturbations in Gut Microbiota Composition in Psychiatric Disorders. JAMA Psychiatry. 2021;78(12):1343-1354. DOI: 10.1001/jamapsychiatry.2021.2573 [Meta-analysis, k=59]
Which test can do it then, and which values say anything?
Briefly: for the question of depression, none. A stool test can answer sensible questions about your digestion, about signs of inflammation in the gut and, in certain situations, about pathogens. What such a test can and cannot do is set out at length in Stool testing and PCR diagnostics.
For mood, by contrast, there is no value that carries a statement. If you are offered a microbiome test meant to classify your mental state, ask to be shown which study supports that classification. From what I can find, it does not exist. What you get is an interpretation and not a finding, and that holds regardless of who offers the test.
A conspicuous stool finding in a depressed person is not an explanation. It is an observation with at least four possible readings: cause, consequence, common root or side effect of the treatment.
Whoever settles on one of these four readings without testing it has not answered the question but skipped it.
And now you know why the next section contains so many numbers. With probiotics it pays to look closely.
Probiotics and prebiotics: the numbers without the marketing
You are standing in the chemist in front of a shelf. One box says psychobiotic. Another says something about the gut-brain axis. And you think: worth a try.
That is a completely reasonable reaction. I only want to give you the numbers to go with it, so you know what you are getting into.
| Analysis | Scope | Result | What is stated alongside |
|---|---|---|---|
| Goh 2019, meta-analysis | 19 randomised trials, 1901 participants | Benefit only in diagnosed major depression | No benefit in the general population. Multi-strain preparations more favourable than single strains |
| Zhao 2025, network meta-analysis | 42 double-blind studies, 2015 to 2022 | Probiotics against placebo SMD minus 0.62 (minus 0.86 to minus 0.42) | Certainty of evidence rated by the authors themselves as moderate to very low. No head-to-head studies |
| Nikolova 2023, pilot RCT | 49 adults, eight weeks, in addition to the ongoing antidepressant | Effect sizes 0.64 to 0.79 in favour of the probiotic group | Feasibility study, not designed for efficacy. First author with a second affiliation to a probiotics manufacturer |
| Meta-analysis Frontiers in Psychiatry 2026 | 6 studies, 341 people not on psychotropic medication | SMD minus 0.38 (minus 0.57 to minus 0.18) | After excluding industry-funded studies SMD minus 0.21 and no longer significant |
The last row is the most honest data point in this whole field. Six studies, 341 people, all without psychotropic medication. A small but measurable advantage. And when you take out the studies funded by manufacturers or containing added substances, a value remains that statistically says nothing any more.
Who did it. A group around Nikolova ran a double-blind pilot study in London between September 2019 and May 2022 with 49 adults who still had depressive symptoms despite ongoing treatment with an antidepressant.
What they observed. For eight weeks, 24 people additionally received a multi-strain probiotic and 25 a placebo. The study figure for the amount was 8 billion colony-forming units per day. The dropout rate was 8 percent, adherence 97.2 percent, and serious side effects did not occur. Effect sizes lay between 0.64 and 0.79 in favour of the probiotic group, with confidence intervals that in part reached up to zero.
What that means for you. Three things are settled: it came in addition to the antidepressant, not instead of it. It was a feasibility study. And the first author is listed in the publication with a second affiliation to a probiotics manufacturer; the disclosure also names funding from this manufacturer for all four authors. That does not devalue the work, but it belongs in the picture.
Nikolova VL et al. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression. JAMA Psychiatry. 2023;80(8):842-847. DOI: 10.1001/jamapsychiatry.2023.1817 [RCT, Pilot, n=49]Which strain is the right one, and what about psychobiotics?
The term psychobiotic comes from research and describes bacterial strains credited with an influence on mood, anxiety or the stress response. It is not a quality seal and not a regulatory classification.
On the strain question there is an unsatisfying but honest answer. Goh 2019 found multi-strain preparations more favourable on average than single strains. Robust direct comparisons of individual strains in depression do not exist. Everything claimed beyond that is extrapolation.
One figure circulates particularly stubbornly online: a 41 percent symptom reduction through a particular Bifidobacterium strain. I know of no primary study from which exactly this figure for this endpoint follows.
What does exist is a small Canadian study in 44 people with irritable bowel syndrome and mild to moderate anxiety or mood symptoms. Under Bifidobacterium longum NCC3001, the depression score on the HAD scale fell by at least two points in 14 of 22 people after six weeks, against 7 of 22 under placebo, at p equal to 0.04. On anxiety and on bowel symptoms the preparation had no significant effect. This is a pilot study in people with irritable bowel syndrome and not a depression study, and staff of a manufacturer were involved as co-authors (Pinto-Sanchez 2017, DOI 10.1053/j.gastro.2017.05.003). So if a percentage figure crosses your path, ask for the study behind it before it convinces you.
Whether a preparation even arrives alive where it is supposed to go is a question of its own. Spore form, capsule, passage through stomach acid and storage are covered in Probiotics: spore form or capsule.
Prebiotics: the second route, and what fibre has to do with it
Who did it. A group around Schmidt had 45 healthy volunteers take one of two prebiotics or a placebo for three weeks, published in Psychopharmacology in 2015.
What they observed. Under galacto-oligosaccharides, GOS for short, the salivary cortisol awakening response came out lower than under placebo. In an attention task, gaze was drawn less strongly to negative compared with positive stimuli. Under fructo-oligosaccharides neither of the two showed up.
What that means for you. A fibre can measurably act at the stress axis in healthy people. The study was randomised, but it measured healthy people and laboratory values, not a depression endpoint. Of two prebiotics tested only one showed anything, and that holds for the preparation used there and not for arbitrary products on the shelf.
Schmidt K et al. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology (Berl). 2015;232(10):1793-801. DOI: 10.1007/s00213-014-3810-0 [RCT, n=45]A second human finding comes from imaging. A group around Tillisch had healthy women eat a fermented milk product with probiotic twice daily for four weeks in 2013, compared with a non-fermented product and with no intervention. In functional magnetic resonance imaging, the probiotic group showed an altered response in a network of affective, viscerosensory and somatosensory cortical areas. There were twelve women in the intervention group, and what was measured was brain activity, not an improvement in mood.
What the microbiome gets to eat at all is covered in Prebiotics and resistant starch. And what is established for sauerkraut, kefir and kimchi in Fermented foods.
In the analyses the reported side effects were mostly mild. That does not hold for everyone. Anyone who is immunosuppressed, for example on biologics, azathioprine or corticosteroids for inflammatory bowel disease, anyone carrying a central venous catheter, anyone severely ill or with a short bowel should have probiotics cleared medically first. In rare cases bloodstream infections have been described under probiotics.
In pregnancy and while breastfeeding the decision likewise belongs in a conversation and not on a drugstore shelf. The same goes for far-reaching dietary changes. For children and adolescents none of the studies cited here applies.
If you try a probiotic, that is unproblematic for most people. It is not a free pass, see the box above.
The mistake would be to leave something else out for it. Not one of these effects was ever measured instead of a treatment. They were all measured in addition.
And now you know why I get louder in the next section. With food the data look different.
The nutrition trail carries furthest
If I were allowed to take one single thing from this whole field, it would be this section. Not because food were magic, but because here there are randomised trials with a clinical endpoint.
Who did it. An Australian group around Jacka followed 67 adults with moderate to severe depression over twelve weeks in BMC Medicine in 2017. 33 received seven counselling sessions with a clinical dietitian, 34 received social contact at the same frequency and duration.
What they observed. The diet group improved considerably more on the MADRS scale, with t(60.7) equal to 4.38, p less than 0.001 and a Cohen's d of minus 1.16. Remission was reached by 32.3 percent, that is 10 of 31, against 8.0 percent, that is 2 of 25. The number needed to treat was 4.1 with a confidence interval from 2.3 to 27.8.
What that means for you. The most important sentence stands in the small print: 55 of the participants were in parallel treatment, 21 with psychotherapy and medication, 9 with psychotherapy only, 25 with medication only. The dietary counselling came in addition. It was not an alternative, and the study never tested it as one either.
Jacka FN et al. A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Med. 2017;15(1):23. DOI: 10.1186/s12916-017-0791-y [RCT, n=67]Who did it. A group around Firth pooled 16 randomised trials of dietary interventions with outcome data for 45,826 participants in Psychosomatic Medicine in 2019.
What they observed. Depressive symptoms decreased significantly, with a Hedges g of 0.162 and a confidence interval from 0.055 to 0.269. The value stayed similar when only high-quality studies were considered. For anxiety symptoms, across 11 studies and 2270 participants, there was no effect. Women benefited more. 15 of the 16 studies examined non-clinical depression.
What that means for you. Averaged across many people the effect is small. That is not a contradiction to SMILES but a different question put to a different population.
Firth J et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. Psychosom Med. 2019;81(3):265-280. DOI: 10.1097/PSY.0000000000000673 [Meta-analysis, k=16, n=45,826]Why minus 1.16 and 0.162 have nothing to do with each other
These two figures must not be compared directly. SMILES examined people with diagnosed moderate to severe depression and measured with the MADRS scale. The meta-analysis by Firth mixes predominantly studies in people without a diagnosis and uses a different effect measure.
Whoever takes the large figure from SMILES and promises it to a general population is calculating wrongly. Whoever takes the small figure from Firth and concludes from it that food is meaningless in depression is calculating wrongly too.
What I take from this for practice, and what I do not
I deliberately give you no meal plan here and no food list with amounts. That would be a prescription, and prescriptions belong in a conversation with a history taken, not in a blog article.
What can be derived from the literature is a direction. SMILES was about a way of eating with more unprocessed foods, more plant variety and fewer heavily processed products. The mechanism that fits it runs through fibre, through the bacteria that turn fibre into short-chain fatty acids, and through inflammatory signals.
Which foods are related to inflammatory markers in studies is covered in Inflammatory foods. On the ketogenic diet in mental illness there is a separate text with the current, still thin body of evidence: Ketogenic diet in mental illness.
There is a point at which healthy eating stops being healthy. When thinking about food governs the day, when eating out becomes a burden, when lists and prohibitions grow while the room to move shrinks, then the measure is working against you.
In depression especially this is a real risk, because control can feel good in the short term. A history of dieting and restriction are risk factors in their own right for disordered eating. If you recognise yourself here, Understanding eating disorders is the better next text than any food list.
And one more thing: nobody became depressed because they ate the wrong way. That equation does not add up, and it hurts people who already look for too much blame in themselves.
Food is not a treatment in depression. It is one adjustable screw that contributed something additional in a randomised trial.
That is less than the headlines promise and more than the restraint of some guidelines suggests. Holding both at once is the most honest position.
And now you know why the nutrition trail is the only one where I speak of evidence without a knot in my stomach.
The inflammation trail and the subgroup idea
There is an observation many people know from their own experience. In a heavy bout of flu, not only strength disappears. Interest disappears too. You want to see nobody, plan nothing, feel nothing.
This behaviour has a name in research: sickness behaviour. It is triggered by inflammatory messengers and it looks astonishingly similar to a depressive episode. From that arose the question of whether inflammation plays a part in some people even without an infection.
Who did it. A group around Osimo analysed 107 studies with 5166 people with depression and 5083 controls in Brain, Behavior and Immunity in 2020. Not only the mean was examined, but also the spread.
What they observed. Raised were CRP with a Hedges g of 0.71, interleukin 6 with 0.61, TNF-alpha with 0.54, interleukin 12 with 1.18, interleukin 18 with 1.97, interleukin 3 with 0.60 and the soluble interleukin 2 receptor with 0.71. For CRP, interleukin 12 and the soluble interleukin 2 receptor the spread was even smaller than in the controls.
What that means for you. The smaller spread is the real surprise. It argues that for these markers the whole distribution shifts, and that it is not just a small inflamed subgroup sticking out. The popular narrative of the few inflamed depressions is at least dented by this.
Osimo EF et al. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-909. DOI: 10.1016/j.bbi.2020.02.010 [Meta-analysis, k=107]And still the subgroup idea stays in the race, because there is a randomised trial on it. It is small, it is old and it remains to this day the most interesting paper in this area.
Who did it. A group around Raison randomised 60 people with treatment-resistant depression double-blind in JAMA Psychiatry in 2013. One half received three infusions of the TNF blocker infliximab over twelve weeks, the other placebo.
For context. Infliximab is a prescription-only biologic. It is licensed among other things for inflammatory bowel disease and for rheumatic disease. For depression there is no licence, so any use would be purely research territory. Known risks include serious infections and the reactivation of tuberculosis, which is why screening is mandatory before any use. I deliberately give no dosages here.
What they observed. Between the groups there was no difference in the overall course. There was, however, a significant interaction with baseline CRP, p equal to 0.01. Above 5 milligrams per litre the course came out in favour of the drug, at 5 or below in favour of placebo. In the exploratory analysis of the high-CRP group, 8 of 13 people responded, that is 62 percent, against 3 of 9 under placebo, that is 33 percent, with p equal to 0.19.
What that means for you. This is the cleanest indication that inflammation might play a part in some people. It is at the same time a very small, exploratory analysis. No treatment proposal follows from it, neither with drugs nor with supplements.
Raison CL et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31-41. DOI: 10.1001/2013.jamapsychiatry.4 [RCT, n=60]So does my CRP value tell me anything?
On its own, no. A CRP value can neither confirm nor rule out a depression. It can raise a question, particularly when it stays raised over a longer period and nobody has looked for the reason.
In clinical practice I see that with longer-standing exhaustion accompanied by abdominal complaints, a look at inflammatory values sometimes opens a trail nobody had followed before. That is my observation and not a study result, and it does not speak against questionnaires, which are well established for tracking the course of a depression. I know the counterexamples from my own consulting room too.
Where inflammation, gut and exhaustion run together I have described separately: Burnout, gut, inflammation and mitochondria. On the stress axis itself there is Cortisol and the HPA axis. And if you want to know how your omega 3 status is actually measured rather than estimated: Measuring the omega 3 index.
Inflammation in depression is not a switch you flip. It is a group difference pointing at a possible route.
The difference between those two sentences is the difference between medicine and marketing.
And now you know why the next section is the most important one for many people. It is about the combination that gets overlooked most often.
When the gut is chronically ill: irritable bowel syndrome and IBD
Imagine planning your day around toilets. You cancel arrangements because you do not know how your gut will decide tomorrow morning. And at some point you are not only exhausted but also sad.
Many people know this pattern. And it is not a weakness of character but well documented.
Who did it. A group around Barberio analysed 77 studies with 30,118 adults with Crohn's disease or ulcerative colitis in Lancet Gastroenterology and Hepatology in 2021, all with validated screening instruments.
What they observed. Anxiety symptoms were found in 32.1 percent, depression symptoms in 25.2 percent. In active disease the figures were 57.6 and 38.9 percent, in inactive disease 38.1 and 24.2 percent. The odds ratios for active against inactive disease were 2.5 for anxiety and 3.1 for depression. Crohn's disease lay somewhat higher than ulcerative colitis in each case. The authors explicitly recommend that gastroenterology screen and treat.
What that means for you. The difference between active and inactive disease is the strongest indication that it is not only the burden of a diagnosis that counts here, but that inflammation itself has a say.
Barberio B et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2021;6(5):359-370. DOI: 10.1016/S2468-1253(21)00014-5 [Meta-analysis, k=77, n=30,118]Who did it. A group around Zamani summarised 73 studies on irritable bowel syndrome in Alimentary Pharmacology and Therapeutics in 2019, after screening 14,926 articles.
What they observed. Anxiety symptoms in 39.1 percent, anxiety disorders in 23 percent, depressive symptoms in 28.8 percent, depressive disorders in 23.3 percent. Against healthy people the odds ratios were 3.11 for anxiety symptoms and 3.04 for depressive symptoms.
What that means for you. Roughly threefold increased odds. Whoever has both is not the exception but a very common case.
Zamani M et al. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132-143. DOI: 10.1111/apt.15325 [Meta-analysis, k=73]No blame follows from these figures. Whoever has a chronic bowel disease carries no psychological responsibility for it. And whoever becomes depressed on top has done nothing wrong, suppressed nothing and processed nothing too little.
The sentence about the illness you made yourself is nowhere supported in this literature. It only does damage.
Gut-directed hypnotherapy: what it has shown, and what it has not
At this point there is a German guideline recommendation, though not where you would expect it. In its 2021 version, the S3 guideline on irritable bowel syndrome from DGVS and DGNM listed gut-directed hypnosis as an evidence-based effective procedure in irritable bowel syndrome [Guideline]. That version is approaching the end of its regular validity period and a revision is due. The statement therefore comes from the most recently published version and may change with an update. On depression it says nothing, because that is not what it is there for.
Who did it. A group around Black analysed 41 randomised trials with 4072 participants on psychological procedures in irritable bowel syndrome in Gut in 2020. A Dutch group around Flik published the IMAGINE trial with 354 people from eleven hospitals in 2019.
What they observed. In the Black analysis, gut-directed hypnotherapy with a relative risk of 0.67, low-contact cognitive behavioural therapy with 0.61 and face-to-face cognitive behavioural therapy with 0.62 came out in front, without any one method being superior to another. The authors consider the risk of bias high and themselves reckon with an overestimate. In the Flik trial, after twelve months 40.8 percent following individual hypnotherapy and 49.5 percent following group hypnotherapy reported adequate symptom relief, against 22.6 percent in the control group.
What that means for you. The endpoint in both papers was bowel symptoms. Not depression.
Black CJ et al. Gut. 2020;69(8):1441-1451. DOI: 10.1136/gutjnl-2020-321191 · Flik CE et al. Lancet Gastroenterol Hepatol. 2019;4(1):20-31. DOI: 10.1016/S2468-1253(18)30310-8 [Meta-analysis, k=41] [RCT, n=354]Depressive symptoms predicted a poorer response
In a follow-up analysis of 448 people with refractory irritable bowel syndrome who had taken part in a randomised trial of 6 against 12 sessions of gut-directed hypnotherapy, 76.3 percent achieved a decrease in the IBS severity score of at least 50 points.
Those who achieved an improvement of at least 30 percent in abdominal pain had a higher baseline level of complaints and a lower baseline value on the depression scale. Those who dropped out had higher anxiety scores.
Hypnotherapy is therefore not an established route to treating a depression. When both are present, the data argue for treating the depression in its own right, in addition and not instead.
Source: Devenney J et al. Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis. Aliment Pharmacol Ther. 2024;59(2):269-277. DOI: 10.1111/apt.17790 [RCT, post hoc analysis, n=448]
What gut-directed hypnotherapy looks like in practice is covered in Gut-directed hypnotherapy in irritable bowel syndrome. On the search for causes in irritable bowel syndrome there is Irritable bowel: finding causes, and on inflammatory bowel disease IBD viewed integratively.
When gut and mood are burdened at the same time, the question of the order is often the wrong question.
Treating both at once is not an alternative point of view in this constellation. It is simply good care, and the Lancet meta-analysis calls for it explicitly.
And now you know why at the end of this article I do not come with a solution but with limits.
The honest limits, and why the restraint has good reasons
Three sentences I consider so important that I write them out separately. They are the core of what this article promises.
First: No microbiome test predicts a depression. Second: No probiotic replaces a treatment. Third: In humans the direction of cause is usually open.
Why no test can do it
Two reasons, both established. The first is the transdiagnostic pattern from the meta-analysis by Nikolova 2021: the same shifts in depression, bipolar disorder, psychosis and anxiety. A marker that is conspicuous in everything is good for nothing in particular.
The second reason is a confounder that often gets overlooked.
Who did it. A group around Maier tested more than a thousand approved drugs against 40 representative gut bacterial strains in the laboratory, published in Nature in 2018 [In vitro].
What they observed. 24 percent of the drugs with a human target inhibited the growth of at least one strain in the test tube. Among those overrepresented were the chemically very diverse antipsychotics.
What that means for you. A conspicuous stool finding in someone taking psychotropic medication can be the consequence of the treatment and not its cause. That is explicitly not an argument against taking it. It is an argument against jumping to conclusions from a test.
Maier L et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623-628. DOI: 10.1038/nature25979 [In vitro]That antidepressants and other drugs can produce gastrointestinal side effects belongs in the same picture. It is a reason to talk about it, not a reason to stop anything. Which drug classes can do what to the gut is covered in Medication and the gut.
What the guidelines say, and why they are so cautious
Three documents, three different statements
- WFSBP and CANMAT 2022 [Guideline]
- An international taskforce with 31 experts from 15 countries assessed nutraceuticals in mental illness. Adjunctive probiotics in unipolar depression received the grade provisionally recommended. The taskforce states explicitly that such agents are recommended as an adjunct within a standard medical treatment model, particularly in severe mental illness.
- German National Care Guideline on Unipolar Depression, version 3.2 [Guideline]
- The German guideline describes stepped treatment by severity, with psychotherapy and pharmacotherapy as the load-bearing pillars, alongside physical activity, low-threshold offers and light therapy. Microbiome, stool tests and probiotics do not appear as a recommendation.
- S3 guideline on irritable bowel syndrome, DGVS and DGNM, 2021 version [Guideline]
- Here stood the one German guideline recommendation that connects gut and mind: psychotherapeutic procedures, among them gut-directed hypnosis, counted as evidence-based effective in irritable bowel syndrome. The version is from 2021 and is being revised. The current status is in the AWMF register.
That the German depression guideline stays silent on the microbiome is not ignorance. It is the clean consequence of thin human evidence. A guideline that took up every plausible idea would no longer be useful to anyone.
I like listing the reasons for this restraint, because they convince me too. No diagnosis-specific pattern. Confounding by medication. Closeness to industry, visible in the fact that one meta-analysis lost its significance as soon as industry-funded studies were excluded. Small, short studies with self-acknowledged low certainty of evidence. And an open direction of causality.
Which came first?
In humans this question is almost never answerable. There are data with a temporal order, and they are interesting, but they prove no cause.
A group around Lurie examined 202,974 people with depression in a large British primary care database in the Journal of Clinical Psychiatry in 2015, each with four matched controls. A single course of antibiotics was associated with an adjusted odds ratio of 1.23 for penicillins, and with more than five courses the value rose to 1.56. For psychosis there was no association. The authors adjusted for the number of infection events, and even so the obvious explanation remains that whoever is ill more often also becomes depressed more often, for many reasons.
The most radical approach to clarifying the direction would be faecal transplantation. An Australian group around Green randomised 15 adults with moderate to severe depression in the Canadian Journal of Psychiatry in 2023, ten receiving a transfer by enema and five a placebo enema. There were no serious side effects and not a single dropout. The study was explicitly not designed to measure efficacy. Whoever reads somewhere that faecal transplantation is established in depression is reading past that sentence.
Nothing in this article is a reason to stop an antidepressant, a mood stabiliser or an antipsychotic, to reduce it or to skip doses. Abrupt discontinuation carries its own risks, from withdrawal symptoms to relapse.
Any change to a prescription belongs in the hands of the prescribing physician and is accompanied. If you are dissatisfied with your treatment, that is a good reason for a conversation and no reason for going it alone.
The same applies to psychotherapy. Nothing here argues for giving up a therapy place or postponing the search for one while you first sort out your gut.
Red flags: nothing waits here
- Thoughts of suicide or the thought that things would be better without you. Get help immediately, see right at the top.
- Self-harm or the urge towards it.
- Psychotic symptoms, for example voices, uncorrectable convictions of guilt, poverty or illness.
- Marked loss of drive over weeks, with everyday life no longer manageable.
- Unintended weight loss or clearly reduced food intake.
- Neglect of self-care, for example personal hygiene, the flat, bills, appointments.
- Blood in the stool, diarrhoea at night, fever, unexplained weight loss belong, independently of all this, in a prompt gastroenterological assessment.
How I handle this topic in the consulting room
When someone comes to me with depression and gut complaints, my first question is not which probiotic it should be. My first question is whether the depression is adequately treated and whether there is a therapy place.
After that I look at the things that are worth looking at regardless of who started with whom. The thyroid first, because an underactive thyroid can explain listlessness, constipation and exhaustion at the same time and can be told apart with a single laboratory value. Then vitamin B12 and folate, sleep, iron and ferritin, vitamin D, inflammatory values, the question of an unrecognised bowel disease and the direction of eating. On sleep there is Sleep and depression, on telling exhaustion apart Burnout or depression, and on the underestimated iron topic Iron deficiency and mental health.
What I do not do: sell a microbiome test meant to classify a mental health diagnosis. That test does not exist, not in my practice either.
And now you know why I do not end this article with a promise but with questions you can ask.
Frequently asked questions
Can depression come from the gut?
It is not that simple. Depression is a serious illness with many causes. What is established is that gut and brain communicate along four routes: the vagus nerve, the immune system, microbial metabolites and the stress axis. In humans it usually remains open whether an altered microbiome is cause, consequence or companion. The gut-brain axis is an additional perspective, not a replacement explanation, and it replaces neither psychotherapy nor psychiatric treatment.
Is it true that 95 percent of serotonin is made in the gut?
By far the largest share of the body's own serotonin does indeed arise in the gut, in the enterochromaffin cells of the mucosa. A study in mice and cell cultures showed that spore-forming gut bacteria can promote this production (Yano 2015, DOI 10.1016/j.cell.2015.02.047). What was measured there were consequences for gut motility and platelets, not for mood.
If serotonin sits in the gut, why does it not lift mood?
Because it stays there. For serotonin from enterochromaffin cells there is to this day no evidence that it crosses the blood-brain barrier. How tightly the blood-brain barrier regulates what arrives upstairs from the gut is described in the review by Osadchiy 2020. Serotonin in the brain is made in the brain itself, from tryptophan. The plausible route from gut to head therefore does not run via serotonin but via the availability of tryptophan and via kynurenine metabolism.
What is the gut-brain axis, in plain words?
Four lines between gut and head. First the vagus nerve as a direct data line. Second the immune system, which speaks through messengers such as interleukin 6. Third microbial metabolites such as short-chain fatty acids from fibre digestion. Fourth the hypothalamic-pituitary-adrenal axis, that is, the stress axis. All four work in both directions: stress changes the microbiome, and the microbiome changes the stress response (Cryan 2019).
What are psychobiotics, and is that an official term?
Psychobiotics is a research term for bacterial strains that studies have credited with an influence on mood, anxiety or the stress response. It comes from the scientific literature and is neither a quality seal nor a regulatory classification. When a product is marketed that way, the name says nothing about whether this particular strain has been studied in depressive symptoms.
Can probiotics do anything for depression, and how strong would the effect be?
The numbers are small and study quality is mixed. A meta-analysis of 19 randomised trials with 1901 participants found a benefit only in diagnosed major depression, not in the general population (Goh 2019). A network meta-analysis of 42 studies reports a standardised mean difference of minus 0.62 for probiotics against placebo, but rates the trustworthiness of the evidence itself as moderate to very low (Zhao 2025). A meta-analysis in Frontiers in Psychiatry 2026 of six studies with 341 people not taking psychotropic medication found minus 0.38; after excluding industry-funded studies, minus 0.21 remained, and with it no significant effect.
Which probiotic strain is best studied for depressive symptoms?
Honest answer: none well enough to derive a recommendation from. The meta-analysis by Goh 2019 found multi-strain preparations more favourable on average than single strains. Robust head-to-head comparisons of individual strains in depression do not exist. On the figure circulating online of a 41 percent symptom reduction through a particular Bifidobacterium strain, I know of no primary study. For Bifidobacterium longum NCC3001 there is a pilot study in 44 people with irritable bowel syndrome in which the depression score fell in 14 of 22 people, against 7 of 22 under placebo (Pinto-Sanchez 2017). That is an irritable bowel study with manufacturer involvement and not a depression study.
Can a stool test or microbiome test show whether my mood comes from the gut?
No. The largest meta-analysis on this covers 59 case-control studies and found no diagnosis-specific pattern but a transdiagnostic one: the same shifts in depression, bipolar disorder, psychosis and anxiety (Nikolova 2021). On top of that comes a strong confounder: in the test tube, 24 percent of drugs with a human target inhibited the growth of at least one gut bacterial strain (Maier 2018). A conspicuous finding can therefore be the consequence of a treatment.
Why do so many people with irritable bowel syndrome also have depressive symptoms?
A meta-analysis of 73 studies found 28.8 percent depressive symptoms and 39.1 percent anxiety symptoms in irritable bowel syndrome, with roughly threefold increased odds compared with healthy people (Zamani 2019). There are several attempts at explanation: constant pain and unpredictability are a burden, the stress axis and pain processing share circuits, and the two reinforce each other. No blame and no imagination follow from this figure.
Is depression more common in Crohn's disease or ulcerative colitis, and why?
Yes. A meta-analysis of 77 studies with 30,118 people with inflammatory bowel disease found 25.2 percent depression symptoms and 32.1 percent anxiety symptoms. With active disease the values rose to 38.9 and 57.6 percent, against 24.2 and 38.1 percent in inactive disease (Barberio 2021). Precisely this difference by disease activity is the strongest hint that inflammation itself plays a part and not only the burden of the diagnosis.
What does inflammation have to do with depression, and does my CRP value tell me anything about it?
A meta-analysis of 107 studies with 5166 affected people and 5083 controls found raised inflammatory markers in depression: CRP with Hedges g 0.71, interleukin 6 with 0.61, TNF-alpha with 0.54 (Osimo 2020). That is a group difference and not a test. A single CRP value can neither confirm nor rule out a depression. In a randomised trial with 60 people with treatment-resistant depression, an advantage for an anti-inflammatory drug appeared only above a baseline CRP of 5 milligrams per litre, and that analysis was exploratory and very small (Raison 2013).
Can I do anything about depressive symptoms with food, and what do the studies show?
The nutrition trail carries furthest. In the SMILES trial, 67 adults with moderate to severe depression received either seven dietary counselling sessions or equally long social contact over twelve weeks, each in addition to ongoing treatment. The diet group improved more clearly, Cohen's d minus 1.16, remission 32.3 against 8.0 percent (Jacka 2017). A meta-analysis of 16 randomised trials with 45,826 participants, by contrast, found only a small Hedges g of 0.162, and 15 of the 16 studies concerned non-clinical depression (Firth 2019). The two figures must not be compared directly.
Can I stop my antidepressant if I get my gut in order?
No. There is no study supporting that, and abrupt discontinuation carries its own risks, from withdrawal symptoms to relapse. Any change to a prescription belongs in the hands of the prescribing physician. In the studies that hint at an added benefit, probiotics or dietary counselling always came in addition to ongoing treatment, never in its place.
How long might it take before anything shows with probiotics or a changed diet?
No recommendation can be derived from this, but the study durations give an orientation. The pilot study with probiotics as an add-on ran eight weeks, and first differences appeared arithmetically from week four (Nikolova 2023). The prebiotic study with galacto-oligosaccharides lasted three weeks (Schmidt 2015). The SMILES nutrition trial ran twelve weeks (Jacka 2017). So if you notice no difference after a week, you have done nothing wrong.
What should I make of personal reports about probiotics in depression?
They deserve to be taken seriously and still do not work as evidence. In the placebo groups of the probiotic trials, depressive symptoms improve too, because time passes, because attention is given and because depression runs in episodes. That is exactly why placebo is subtracted out. If something does you good and does no harm, that is a good reason to keep it. It is not a reason to change an ongoing treatment.
I take an antidepressant and still have stomach and bowel complaints. What could be behind that?
Stomach and bowel complaints are among the most common side effects of many antidepressants, especially in the first weeks. In addition, a laboratory screen showed that many non-antibiotic drugs can inhibit the growth of gut bacteria (Maier 2018). That is not an argument against taking them, but a reason to raise the complaints. Timing of intake, accompanying measures and the question of whether a different preparation fits better belong in the conversation with the prescribing practice.
Where this topic connects to the rest of the body
Gut and mood do not stand alone. They hang on sleep, iron, inflammation, the nervous system and on the question of how permeable a mucous membrane happens to be. These texts belong with it, in my view.
Gut-brain axis and the vagus
The mechanism in detail, plus breathing, cold and transcutaneous stimulation
Irritable bowel: finding causes
Subtypes, triggers and the order in which searching pays off
IBD viewed integratively
Crohn's disease and ulcerative colitis beyond pure anti-inflammatory treatment
Gut-directed hypnotherapy
How the procedure runs and for whom it paid off in studies
Probiotics: form and survival
Spore form or capsule, stomach acid, storage and what of it counts
Prebiotics and resistant starch
What your bacteria actually get to eat
Stool testing and PCR diagnostics
Which question a test can answer and which it cannot
Leaky gut and zonulin
Permeability of the lining, measurement methods and their limits
L-glutamine and butyrate
What the gut lining supplies its own cells with
Vagus nerve and stress regulation
Why recovery is an active process and not doing nothing
Sleep and depression
The connection that runs both ways and often tips first
Iron deficiency and mental health
Why ferritin is overlooked more often than assumed in loss of drive
Scientific sources
- Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022;23(6):424-455. PMID: 35311615 · DOI: 10.1080/15622975.2021.2013041 [Guideline]
- Bundesärztekammer, Kassenärztliche Bundesvereinigung, AWMF. Nationale VersorgungsLeitlinie Unipolare Depression. German National Care Guideline on Unipolar Depression, version 3.2, July 2023, valid until 29 September 2027. AWMF register no. nvl-005. AWMF register [Guideline]
- Layer P, Andresen V, Allescher H, Bischoff SC, Classen M, Elsenbruch S et al. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der DGVS und der DGNM. German S3 guideline on irritable bowel syndrome. Z Gastroenterol. 2021;59(12):1323-1415. AWMF 021/016. PMID: 34891206 · DOI: 10.1055/a-1591-4794 [Guideline]
- Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877-2013. PMID: 31460832 · DOI: 10.1152/physrev.00018.2018 [Mechanism Review]
- Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461-478. PMID: 31123355 · DOI: 10.1038/s41575-019-0157-3 [Mechanism Review]
- Osadchiy V, Martin CR, Mayer EA. Gut Microbiome and Modulation of CNS Function. Compr Physiol. 2020;10(1):57-72. PMID: 31853944 · DOI: 10.1002/cphy.c180031 [Mechanism Review]
- Dinan K, Dinan T. Antibiotics and mental health: The good, the bad and the ugly. J Intern Med. 2022;292(6):858-869. PMID: 35819136 · DOI: 10.1111/joim.13543 [Systematic Review]
- Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050-5. PMID: 21876150 · DOI: 10.1073/pnas.1102999108 [In vivo, mouse]
- Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263-75. PMID: 15133062 · DOI: 10.1113/jphysiol.2004.063388 [In vivo, mouse]
- Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry. 2016;21(6):786-96. PMID: 27067014 · DOI: 10.1038/mp.2016.44 [In vivo, mouse]
- Kelly JR, Borre Y, O'Brien C, Patterson E, El Aidy S, Deane J et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016;82:109-18. PMID: 27491067 · DOI: 10.1016/j.jpsychires.2016.07.019 [In vivo, rat]
- Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-76. PMID: 25860609 · DOI: 10.1016/j.cell.2015.02.047 [In vivo, mouse] [In vitro]
- Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623-628. PMID: 29555994 · DOI: 10.1038/nature25979 [In vitro]
- Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-632. PMID: 30718848 · DOI: 10.1038/s41564-018-0337-x [Cohort, n=1054 plus 1070]
- Radjabzadeh D, Bosch JA, Uitterlinden AG, Zwinderman AH, Ikram MA, van Meurs JBJ et al. Gut microbiome-wide association study of depressive symptoms. Nat Commun. 2022;13(1):7128. PMID: 36473852 · DOI: 10.1038/s41467-022-34502-3 [Cohort, n=1054 plus 1539]
- Lurie I, Yang YX, Haynes K, Mamtani R, Boursi B. Antibiotic exposure and the risk for depression, anxiety, or psychosis: a nested case-control study. J Clin Psychiatry. 2015;76(11):1522-8. PMID: 26580313 · DOI: 10.4088/JCP.15m09961 [Cohort, case-control, n=202,974]
- Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis. JAMA Psychiatry. 2021;78(12):1343-1354. PMID: 34524405 · DOI: 10.1001/jamapsychiatry.2021.2573 [Meta-analysis, k=59]
- Marx W, McGuinness AJ, Rocks T, Ruusunen A, Cleminson J, Walker AJ et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021;26(8):4158-4178. PMID: 33230205 · DOI: 10.1038/s41380-020-00951-9 [Meta-analysis, k=101, n=10,912]
- Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-909. PMID: 32113908 · DOI: 10.1016/j.bbi.2020.02.010 [Meta-analysis, k=107]
- Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. PMID: 22945416 · DOI: 10.1001/2013.jamapsychiatry.4 [RCT, n=60]
- Goh KK, Liu YW, Kuo PH, Chung YE, Lu ML, Chen CH. Effect of probiotics on depressive symptoms: A meta-analysis of human studies. Psychiatry Res. 2019;282:112568. PMID: 31563280 · DOI: 10.1016/j.psychres.2019.112568 [Meta-analysis, k=19]
- Zhao S, Liang S, Tao J, Peng Y, Chen S, Wai HKF et al. Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis. Nutr Rev. 2025;83(1):72-82. PMID: 38219239 · DOI: 10.1093/nutrit/nuad171 [Meta-analysis, network, k=42]
- Nikolova VL, Cleare AJ, Young AH, Stone JM. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2023;80(8):842-847. PMID: 37314797 · DOI: 10.1001/jamapsychiatry.2023.1817 [RCT, n=49]
- Haiyan L, Dan W, Xiaochao W, Xiuxiu C, Ye L, Zhiguo C, Ting L. Efficacy of probiotic intervention in unmedicated depression: a systematic review and meta-analysis. Front Psychiatry. 2026;16:1608238. PMID: 41573044 · DOI: 10.3389/fpsyt.2025.1608238 [Meta-analysis, k=6, n=341]
- Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153(2):448-459.e8. PMID: 28483500 · DOI: 10.1053/j.gastro.2017.05.003 [RCT, pilot, n=44]
- Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PWJ. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology (Berl). 2015;232(10):1793-801. PMID: 25449699 · DOI: 10.1007/s00213-014-3810-0 [RCT, n=45]
- Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144(7):1394-401. PMID: 23474283 · DOI: 10.1053/j.gastro.2013.02.043 [RCT, n=36]
- Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15(1):23. PMID: 28137247 · DOI: 10.1186/s12916-017-0791-y [RCT, n=67]
- Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. Psychosom Med. 2019;81(3):265-280. PMID: 30720698 · DOI: 10.1097/PSY.0000000000000673 [Meta-analysis, k=16, n=45,826]
- Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(5):359-370. PMID: 33721557 · DOI: 10.1016/S2468-1253(21)00014-5 [Meta-analysis, k=77, n=30,118]
- Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132-143. PMID: 31157418 · DOI: 10.1111/apt.15325 [Meta-analysis, k=73]
- Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441-1451. PMID: 32276950 · DOI: 10.1136/gutjnl-2020-321191 [Meta-analysis, network, k=41]
- Flik CE, Laan W, Zuithoff NPA, van Rood YR, Smout AJPM, Weusten BLAM, Whorwell PJ, de Wit NJ. Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(1):20-31. PMID: 30473202 · DOI: 10.1016/S2468-1253(18)30310-8 [RCT, n=354]
- Devenney J, Hasan SS, Morris J, Whorwell PJ, Vasant DH. Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis. Aliment Pharmacol Ther. 2024;59(2):269-277. PMID: 37927144 · DOI: 10.1111/apt.17790 [RCT, post hoc analysis, n=448]
- Green JE, Berk M, Mohebbi M, Loughman A, McGuinness AJ, Castle D et al. Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial. Can J Psychiatry. 2023;68(5):315-326. PMID: 36637229 · DOI: 10.1177/07067437221150508 [RCT, Pilot, n=15]
- Sun Y, Fan C, Lei D. Association between gut microbiota and postpartum depression: A bidirectional Mendelian randomization study. J Affect Disord. 2024;362:615-622. PMID: 39029663 · DOI: 10.1016/j.jad.2024.07.057 [Cohort, genetic instrumental variables]
- The strongest causal evidence comes from animal experiments. Bravo 2011 with the vagotomy, Sudo 2004 with the germ-free mice and the two transfer studies all arose in animal models. They show that a mechanism is possible. They do not show that it takes hold in a particular person.
- In humans the findings are smaller and less uniform. Two large European cohorts find Coprococcus, yet the largest meta-analysis finds the same pattern across four different diagnoses. Diagnosis specificity is therefore not established.
- With probiotics the effect disappears as soon as industry-funded studies are excluded. In the meta-analysis in Frontiers in Psychiatry 2026 the standardised mean difference fell from minus 0.38 to minus 0.21, and the result was no longer significant.
- Conflict of interest in a cited pilot study. The first author of the London add-on study from 2023 is listed in the publication with a second affiliation to a probiotics manufacturer, and the declaration of interests names funding from the same manufacturer for all four authors. Both stand in the publication and belong here too.
- The network meta-analysis compares indirectly. Zhao 2025 places probiotics and antidepressants side by side without a single head-to-head study existing. The authors themselves downgrade the certainty of evidence as far as very low. Whoever reads from this that probiotics are as good as antidepressants is reading something into it.
- Short-chain fatty acids are mechanistically plausible and barely tested in humans. The Leuven review states explicitly that studies testing short-chain fatty acids directly as mediators of mental effects are sparse.
- Mendelian randomisation does not yet carry here. The 2024 paper on postpartum depression names six bacterial features, limits itself to a European population and works, like all microbiome MR studies, with weak instruments. It stands here as an example of an open methodological question, not as evidence.
- Antibiotic data show temporal order, not cause. Whoever needs antibiotics more often is ill more often, and being ill is itself related to depression. The authors adjusted, and the problem remains.
- Faecal transplantation in depression is at the research stage. 15 people, feasibility shown, efficacy explicitly not examined.
- On leaky gut and lipopolysaccharide signals in depression I deliberately make no statement here. In the transfer study by Kelly a corresponding marker was measured alongside, but a replicated relationship with the severity of a depression cannot be derived from it. On the matter itself see Leaky gut and zonulin.
- Commercial disclosure. ViveCura offers diagnostics and support in the area of gut health. That is exactly why this article states explicitly that no test of this kind can detect or predict a depression, not even one from my practice.
- What deliberately does not stand here. No dosing recommendation, no meal plan, no treatment protocol and no advice to change, reduce or stop an existing medication. No sentence in this article argues for postponing or replacing psychotherapy or psychiatric treatment. What I describe from my consulting room is marked as an observation and is not a study result.